Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis.

ABSTRACT:

Background

Budesonide multimatrix (MMX) system has been approved for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), and offers potential safety benefits over more commonly utilized corticosteroid therapies.

Objectives

In a real-world setting we aimed to evaluate the proportion of UC patients treated with budesonide MMX who had an inadequate clinical response, defined as requiring transition to prednisone, and to identify any predictors of inadequate response.

Methods

We performed a single-center retrospective cohort study evaluating adult patients with UC, ≥18 years of age, who were treated with budesonide MMX. We used bivariate and multivariable analyses to identify predictors of inadequate response to budesonide MMX.

SUBMITTER: Greenberg S 

PROVIDER: S-EPMC6751477 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature